Hutchmed gets NMPA approval for ATLED in FGFR2+ intrahepatic cholangiocarcinoma
HUTCHMED announced NMPA approval for ATLED (fanregratinib) for patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.